Navigation Links
VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
Date:4/23/2013

SEATTLE, April 23, 2013 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. today announced the appointment of James Kyle Bryan , M.D. as Chief Medical Officer.  A hematologist and medical oncologist, Dr. Bryan brings more than 20 years of oncology drug discovery and development experience in the pharmaceutical and biotechnology industry to VentiRx.  This includes extensive operational and strategic leadership work in his previous roles as Vice President of Global Product Development at PPD, Inc., a global contract research organization, and as Vice President of Medical Affairs at Seattle Genetics.

(Logo:  http://photos.prnewswire.com/prnh/20120828/SF63676LOGO)

"Kyle will be integral in directing our clinical development efforts, which will  include our ongoing randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent ovarian cancer and our upcoming Phase 2 trial of VTX-2337 in head and neck cancer patients," said Robert Hershberg , M.D., Ph.D., Chief Executive Officer of VentiRx. "His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward.  We are delighted to have him join the VentiRx team."

Board-certified in medical oncology, hematology and internal medicine, Dr. Bryan currently serves on the clinical faculty of medicine for hematology and oncology at the University of Washington Medical Center.  Dr. Bryan received a B.S. in biochemistry and an M.D. from Louisiana State University and completed his fellowship in hematology and oncology at the University of Washington.

About VentiRx Pharmaceuticals
VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases.  The Company's lead product candidate is VTX-2337, a small molecule TLR8 agonist for the treatment of cancer. VentiRx has an exclusive, world-wide collaboration with Celgene Corporation for VTX-2337. VentiRx is a privately held organization based in Seattle, Washington.  For additional information, please visit www.ventirx.com.

 


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
2. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
3. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
4. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
5. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
6. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
7. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
8. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
9. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
10. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
11. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has received ... SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive seizure ... periods of rest. A lightweight, non-invasive monitor is placed on the belly of ...
(Date:2/23/2017)... 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company ... announced that Linda Marbán, Ph.D, president and chief executive officer, ... Cowen and Company 37th Annual Health Care ... Boston, MA 29th Annual ... (12:00 pm ET) Dana Point, CA ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a neurotechnology ... for research and clinical applications. The terms of the transaction were not disclosed. ...
Breaking Biology Technology:
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/23/2017)... latest mobile market research from Acuity Market Intelligence reveals ... average price of a biometric smartphone decreased from $849 ... are now 120 sub-$150 models on the market at ... a year ago at an average price of $127. ... Acuity Market Intelligence Principal, "Biometric Smartphones are a global ...
Breaking Biology News(10 mins):